mTOR Inhibition in Kidney Cancer

Anil Kapoor


Treatment for metastatic renal cell carcinoma (mRCC) has undergone a paradigm shift in the last few years from the mainstay of cytokine therapy for many years (interferon- alpha and interleukin -2 ) to new targeted therapies including vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors. These new VEGF inhibitors include sunitinib (Sutent) and sorafenib (Nexavar), with sunitinib demonstrating efficacy as first line therapy for mRCC in good to intermediate prognosis patients (ref). The mTOR inhibitor temsirolimus (Torisel) has been shown to prolong overall survival compared to interferon – alpha in poor prognosis patients.

Full Text:



Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)